{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:21:25Z","timestamp":1791998485945,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.canlet.2021.10.024","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T19:15:04Z","timestamp":1634843704000},"page":"161-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Induction of IL-6R\u03b1 by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma"],"prefix":"10.1016","volume":"524","author":[{"given":"Zichan","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangxin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-8166","authenticated-orcid":false,"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.10.024_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.10.024_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2018.02.016","article-title":"The role of molecular enrichment on future therapies in hepatocellular carcinoma","volume":"69","author":"Nault","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2021.10.024_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2021.10.024_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2021.10.024_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/2159-8290.CD-NB2017-070","article-title":"Regorafenib approved for liver cancer,","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.10.024_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.10.024_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2021.10.024_bib8","first-page":"773","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer, Nature reviews","volume":"18","author":"Jones","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2021.10.024_bib9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/hep.30774","article-title":"IL-6 trans-signaling controls liver regeneration after partial hepatectomy","volume":"70","author":"Fazel Modares","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2021.10.024_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1749-6632.2002.tb04093.x","article-title":"Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma","volume":"963","author":"Giannitrapani","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2021.10.024_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ijc.28337","article-title":"Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study","volume":"134","author":"Ohishi","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2021.10.024_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","article-title":"Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production","volume":"317","author":"Naugler","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.10.024_bib13","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1158\/0008-5472.CAN-12-2353","article-title":"Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma","volume":"73","author":"Ara","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.10.024_bib14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/cas.12478","article-title":"Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated\/NF-kappaB pathway activation","volume":"105","author":"Yan","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2021.10.024_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12943-019-0972-8","article-title":"Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer","volume":"18","author":"Ham","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2021.10.024_bib16","doi-asserted-by":"crossref","first-page":"152565","DOI":"10.1016\/j.prp.2019.152565","article-title":"Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib","volume":"215","author":"Yang","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.canlet.2021.10.024_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/jjco\/hyx103","article-title":"High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma","volume":"47","author":"Shao","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.10.024_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.10.024_bib19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: from physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2021.10.024_bib20","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/med.21761","article-title":"The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy","volume":"41","author":"Garg","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.canlet.2021.10.024_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jare.2020.07.004","article-title":"Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"26","author":"Lee","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2021.10.024_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine--40 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.10.024_bib23","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1074\/jbc.M113.466169","article-title":"Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling","volume":"288","author":"Baran","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.024_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bcp.2015.06.009","article-title":"Biological effects of interleukin-6: clinical applications in autoimmune diseases and cancers","volume":"97","author":"Ho","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.10.024_bib25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1053\/gast.2000.20236","article-title":"Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration","volume":"119","author":"Peters","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2021.10.024_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.28874","article-title":"IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice","volume":"65","author":"Bergmann","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2021.10.024_bib27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4049\/jimmunol.1900876","article-title":"Cutting edge: IL-6-Driven immune dysregulation is strictly dependent on IL-6R alpha-chain expression","volume":"204","author":"Mufazalov","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.10.024_bib28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.immuni.2016.04.003","article-title":"CD5 binds to interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote cancer","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2021.10.024_bib29","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gku1111","article-title":"The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools","volume":"43","author":"Dreos","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2021.10.024_bib30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1128\/MCB.24.3.1365-1377.2004","article-title":"Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response","volume":"24","author":"Jiang","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.10.024_bib31","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.7150\/ijbs.32550","article-title":"Melatonin increases the sensitivity of hepatocellular carcinoma to sorafenib through the PERK-ATF4-beclin1 pathway","volume":"15","author":"Zhou","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2021.10.024_bib32","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15252\/embr.201642195","article-title":"The integrated stress response","volume":"17","author":"Pakos-Zebrucka","year":"2016","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2021.10.024_bib33","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1128\/MCB.01080-06","article-title":"The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress","volume":"27","author":"Rahmani","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.10.024_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2021.10.024_bib35","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.canlet.2021.10.024_bib36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/eji.1830230515","article-title":"Serum soluble interleukin-6 receptor in MRL\/lpr mice is elevated with age and mediates the interleukin-6 signal","volume":"23","author":"Suzuki","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2021.10.024_bib37","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","article-title":"Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma","volume":"15","author":"Shinriki","year":"2009","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.canlet.2021.10.024_bib38","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ejca.2010.12.019","article-title":"Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance","volume":"47","author":"Krumbach","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2021.10.024_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.28251","article-title":"Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells","volume":"63","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2021.10.024_bib40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.28574","article-title":"Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis","volume":"64","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2021.10.024_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-kappaB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.10.024_bib42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00281-021-00861-0","article-title":"The two facets of gp130 signalling in liver tumorigenesis","volume":"43","author":"Schmidt-Arras","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.canlet.2021.10.024_bib43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2005.04.014","article-title":"IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis","volume":"121","author":"Maeda","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.10.024_bib44","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.2147\/OTT.S262089","article-title":"IL-6\/STAT3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer Stem cells","volume":"13","author":"Li","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2021.10.024_bib45","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/jcmm.16256","article-title":"Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation","volume":"25","author":"Jiang","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2021.10.024_bib46","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1074\/jbc.M116.762021","article-title":"Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6 trans-signaling","volume":"292","author":"Chehboun","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.024_bib47","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1074\/jbc.M210044200","article-title":"Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF","volume":"278","author":"Schuster","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.024_bib48","doi-asserted-by":"crossref","first-page":"18442","DOI":"10.1074\/jbc.M114.568857","article-title":"The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates interleukin-6 receptor-dependent but retains CNTF receptor-dependent signaling via glycoprotein 130 (gp130)\/leukemia inhibitory factor receptor (LIFR)","volume":"289","author":"Wagener","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.024_bib49","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.4049\/jimmunol.0901464","article-title":"The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling","volume":"183","author":"Crabe","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.10.024_bib50","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1074\/jbc.M112.432955","article-title":"An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer","volume":"288","author":"Garbers","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.10.024_bib51","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.4049\/jimmunol.1600627","article-title":"Soluble IL-6 receptor and IL-27 subunit p28 protein complex mediate the antiviral response through the type III IFN pathway","volume":"197","author":"Yang","year":"2016","journal-title":"J. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:00:51Z","timestamp":1759593651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521005346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0304383521005346"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.024","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction of IL-6R\u03b1 by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}